Argus Finds Adverse Events. AI Monitoring Finds Bad Answers. They’re Not the Same Job.
On March 11, 2026, the FDA retired the FDA Adverse Event Reporting System, the database that has anchored US drug
General
General
The label says one thing, the patient hears another: the small print that quietly rewrites therapy
There is a particular kind of failure mode in medicine that doesn’t look dramatic from the outside. No needles in
Off-Label Revenue Is Real Revenue. It’s Also Fragile Revenue.
In April 2018, the Department of Justice intervened in five whistleblower lawsuits against Insys Therapeutics, alleging the company had built
The Call Before the Call: What AI Monitoring Tells Field Sales Teams Before the Rep Walks In
About two-thirds of practicing US physicians, roughly 650,000 people, now use a chatbot called OpenEvidence to help decide how to
Off-Label Use Can Boost Sales. It Can Also Break Forecasts.
The Short Answer In November 2013, Johnson & Johnson agreed to pay more than $2.2 billion to resolve criminal and
How to Evaluate an AI Brand Monitoring Vendor: A Buyer’s Checklist for Medical Affairs
The short answer: An AI brand monitoring RFP for a pharma organization needs to test a vendor on eight things:
The 20 Drug Brands AI Talks About Most (And What It Gets Wrong)
Ask ChatGPT about a drug interaction at 11pm and you get an answer in four seconds. No waiting room, no
The Drugs AI Talks About Most (And the Blind Spot No One’s Watching)
Ask ChatGPT what to take for Type 2 diabetes and there’s a good chance it says Ozempic before it says
The Call Before the Call: What AI Monitoring Tells Field Sales Teams Before the Rep Walks In
About two-thirds of practicing US physicians, roughly 650,000 people, now use a chatbot called OpenEvidence to help decide how to
Agentic AI Comes to Drug Safety: What Veeva’s AI Agents Mean for Pharmacovigilance Teams
The Short Answer Veeva Systems is running two parallel agentic AI programs in drug safety at once, and they are
When Your Fastest-Growing Market Exists Outside the Label
How semaglutide and tirzepatide built a combined obesity-and-diabetes franchise worth tens of billions of dollars largely on off-label and compounded
FDA and EMA Have No AI-Generated Drug Content Rule. Here’s What Already Governs It
A compliance primer for Medical Affairs, Regulatory Affairs, Pharmacovigilance, and Brand teams The Short Answer Neither FDA nor EMA has
